<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2007</study_start_year><condition>Colorectal Neoplasms</condition><condition>Colorectal, Cancer</condition><disease>Colorectal Neoplasms</disease><disease>Colorectal, Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2047203</full_dataset_link><location>Japan</location><study_start_month>10</study_start_month><keyword>Irinotecan</keyword><keyword>S-1, Bevacizumab, Irinotecan</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer</name><description>Phase II trial of combination therapy with S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer</description><dates><creation>2007-10-15</creation></dates><accession>2047203</accession><cross_references><ClinicalTrials___gov>NCT00569335</ClinicalTrials___gov></cross_references></HashMap>